NCT07046494Phase 2Completed

Study Evaluating the Efficacy and Safety of RAP-219 in Adult Participants With Bipolar I Disorder

Study sponsor: Rapport Therapeutics Inc. · RAPP

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-08-05Actual
Enrollment · participants253Actual
Source updated2026-10-26Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Recruitment status changed

Before: Active not recruiting. After: Completed.

Check registry source

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 250 participants (planned). After: 253 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Sep 2026. After: 5 Aug 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source

· 2 fields changed

Planned enrollment increased by 26 participants

Before: 224 participants (planned). After: 250 participants (planned).

Primary completion date changed

Before: Oct 2026. After: Sep 2026.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview